On September 2, 2026 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, Sept. 09, 2026, at 2:15 p.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.

(Press release, Merck & Co, SEP 2, 2026, View Source [SID1234670535])

On September 2, 2026 Mabqi reported the participation of Anne Chevrel, Johanna Marines and Cécile Durand in the Festival of Biologics 2026, taking place from October 13 to 15 in Basel, Switzerland—Europe’s largest biologics event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our company will showcase its latest advances with a strong presence at this year’s congress.
Not 1 but 2 oral presentations!
– Next-Generation Tumor-Specific Anti-CD30 ADC as a New Therapy in Hemato-Oncology – Anne Chevrel, Head of Discovery – Wednesday, October 14 at 12.10.
– A Novel Pan-Cancer TRPV6-Targeted Therapy Driving Antitumor Activity Through Ion Channel Modulation– Johanna Marines, Head of Preclinical Development, Wednesday, October 14 at 12.30.

Two Poster presentations:
– MQI-201: A pan cancer immunotherapy targeting TRPV6 to convert cold tumors into hot tumors
– MQI-181: Tumor-specific anti-CD30 ADC limiting sink effect and demonstrating enhanced in vivo efficacy

Don’t miss the opportunity to meet our team at our booth in the Choose France Pavillon. Feel free to drop us a line or to schedule or contacts us through the networking app to schedule a meeting.

This major international gathering brings together over 3,000 experts from across the biologics and ATMP value chain, covering everything from early-stage discovery to commercialization. The event spans antibody therapies, cell and gene therapies, immunotherapies, and biosimilars.
We’re proud to be part of this vibrant community of scientists, innovators, and industry leaders shaping the future of large molecule therapeutics.

(Press release, Mabqi, SEP 2, 2026, View Source [SID1234670534])

On September 2, 2026 Mabqi reported its CEO Sylvain Yon, will attend the 26th Annual Biotech in Europe Forum, taking place in Basel on October 7–8 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Held as part of Sachs Autumn Life Sciences Week, the forum will bring together senior executives, investors, entrepreneurs and industry experts from across the global life sciences ecosystem.

The event will provide a valuable opportunity to discuss with investors and biopharmas, explore strategic partnerships and connect with companies developing the next generation of healthcare innovations.

Sylvain Yon looks forward to meeting industry peers, investors and potential partners in Basel.

Feel free to drop us a line or to schedule or contacts us through the networking app to schedule a meeting.

(Press release, Mabqi, SEP 2, 2026, View Source [SID1234670533])

On September 2, 2026 Johnson & Johnson (NYSE: JNJ) reported it will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17th, 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day.

The audio webcast replay will be available approximately 48 hours after the webcast.

(Press release, Johnson & Johnson, SEP 2, 2026, View Source [SID1234670532])

On September 2, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, reported that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC) appears longer than originally anticipated based on the assumptions underlying the study design.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pivotal Phase III study is a randomized, double-blind, placebo-controlled study evaluating Namodenoson in patients with advanced HCC and underlying Child-Pugh B7 cirrhosis. Patients are randomized 2:1 to receive Namodenoson or placebo, with overall survival as the primary efficacy endpoint. The observed survival reflects the pooled, blinded study population and includes patients receiving both Namodenoson and placebo. Accordingly, no conclusions regarding treatment efficacy or differences between the study arms can be drawn from these data at this stage.

In view of the longer-than-anticipated survival observed in the study population, Can-Fite is evaluating an earlier timing for the study’s planned interim analysis. The interim analysis will enable an independent assessment of overall survival between the Namodenoson and placebo treatment groups in accordance with the study’s statistical analysis plan and applicable regulatory requirements.

"We are encouraged by the longer overall survival being observed among patients participating in this pivotal study," said Motti Farbstein Can-Fite CEO & CFO. "While the study remains blinded and these observations cannot predict the treatment effect of Namodenoson, we believe that conducting the planned interim analysis earlier could provide important information regarding the potential clinical benefit of Namodenoson in this patient population with substantial unmet medical need."

About Namodenoson

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson is currently being evaluated in a pivotal Phase 3 trial for advanced liver cancer, concluded successfully a Phase 2a study in pancreatic cancer and is enrolling patients in a Phase 2b trial for the treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH). A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential expression may be one of the important factors that accounts for the excellent safety profile of the drug.

(Press release, Can-Fite BioPharma, SEP 2, 2026, View Source [SID1234670531])